[Emerging disease-modifying therapies for multiple sclerosis]

Research output: Contribution to journalArticle

Abstract

Multiple sclerosis(MS) is an inflammatory demyelinating disease of the central nervous system with yet undetermined etiology. The incidence of MS is rapidly rising in Japan, and in addition to four already-approved disease-modifying therapies (DMTs), namely interferon β1b, interferonβ1a, fingolimod and natalizumab, several new DMTs are currently under clinical trials. In this article, emerging DMTs such as alemtuzumab, dimethyl fumarate and teriflunomide as well as fampridine, a novel symptomatic treatment for gait disturbance, and anti-LINGO-1 monoclonal antibody, a possible candidate for future remyelination therapy, will be reviewed. Future treatment strategies such as induction therapy and combined therapy for MS will also be discussed.

Original languageEnglish
Pages (from-to)2031-2037
Number of pages7
JournalNihon rinsho. Japanese journal of clinical medicine
Volume72
Issue number11
Publication statusPublished - 2014 Nov 1
Externally publishedYes

Fingerprint

Multiple Sclerosis
Therapeutics
Demyelinating Diseases
Gait
Interferons
Japan
Central Nervous System
Monoclonal Antibodies
Clinical Trials
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

[Emerging disease-modifying therapies for multiple sclerosis]. / Nakahara, Jin.

In: Nihon rinsho. Japanese journal of clinical medicine, Vol. 72, No. 11, 01.11.2014, p. 2031-2037.

Research output: Contribution to journalArticle

@article{8e2aa6a01b2348bf9291e9b32363ead5,
title = "[Emerging disease-modifying therapies for multiple sclerosis]",
abstract = "Multiple sclerosis(MS) is an inflammatory demyelinating disease of the central nervous system with yet undetermined etiology. The incidence of MS is rapidly rising in Japan, and in addition to four already-approved disease-modifying therapies (DMTs), namely interferon β1b, interferonβ1a, fingolimod and natalizumab, several new DMTs are currently under clinical trials. In this article, emerging DMTs such as alemtuzumab, dimethyl fumarate and teriflunomide as well as fampridine, a novel symptomatic treatment for gait disturbance, and anti-LINGO-1 monoclonal antibody, a possible candidate for future remyelination therapy, will be reviewed. Future treatment strategies such as induction therapy and combined therapy for MS will also be discussed.",
author = "Jin Nakahara",
year = "2014",
month = "11",
day = "1",
language = "English",
volume = "72",
pages = "2031--2037",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "11",

}

TY - JOUR

T1 - [Emerging disease-modifying therapies for multiple sclerosis]

AU - Nakahara, Jin

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Multiple sclerosis(MS) is an inflammatory demyelinating disease of the central nervous system with yet undetermined etiology. The incidence of MS is rapidly rising in Japan, and in addition to four already-approved disease-modifying therapies (DMTs), namely interferon β1b, interferonβ1a, fingolimod and natalizumab, several new DMTs are currently under clinical trials. In this article, emerging DMTs such as alemtuzumab, dimethyl fumarate and teriflunomide as well as fampridine, a novel symptomatic treatment for gait disturbance, and anti-LINGO-1 monoclonal antibody, a possible candidate for future remyelination therapy, will be reviewed. Future treatment strategies such as induction therapy and combined therapy for MS will also be discussed.

AB - Multiple sclerosis(MS) is an inflammatory demyelinating disease of the central nervous system with yet undetermined etiology. The incidence of MS is rapidly rising in Japan, and in addition to four already-approved disease-modifying therapies (DMTs), namely interferon β1b, interferonβ1a, fingolimod and natalizumab, several new DMTs are currently under clinical trials. In this article, emerging DMTs such as alemtuzumab, dimethyl fumarate and teriflunomide as well as fampridine, a novel symptomatic treatment for gait disturbance, and anti-LINGO-1 monoclonal antibody, a possible candidate for future remyelination therapy, will be reviewed. Future treatment strategies such as induction therapy and combined therapy for MS will also be discussed.

UR - http://www.scopus.com/inward/record.url?scp=84922325733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922325733&partnerID=8YFLogxK

M3 - Article

C2 - 25518389

AN - SCOPUS:84922325733

VL - 72

SP - 2031

EP - 2037

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 11

ER -